Literature DB >> 2380406

Application of immunoblotting to detect soluble Pneumocystis carinii antigen(s) in bronchoalveolar lavage of patients with Pneumocystis pneumonia and AIDS.

K K Sethi1.   

Abstract

The technique of immunoblotting for detecting soluble Pneumocystis carinii antigen(s) in bronchoalveolar lavage fluid specimens from patients with AIDS and Pneumocystis pneumonia was evaluated. A soluble 67 kilodalton polypeptide that was immunoreactive with an anti-P carinii monoclonal antibody (2G2) was found in the supernatants of 26 lavage samples from patients with pneumocystosis. Intact organisms in lavage sediments were detected by methenamine silver or immunofluorescence staining procedures. The diagnostic use of this technique was shown in four cases in which lavage sediments proved negative for intact Pneumocystis carinii organisms on first examination; 2G2 reactive soluble antigen, however, was identified in the immunoblots of the supernatants from the same samples. It is concluded that immunoblotting of bronchoalveolar lavage specimens using 2G2 monoclonal antibody as a detection probe may be a useful adjunct to the morphological demonstration of organisms by special staining procedures.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2380406      PMCID: PMC502586          DOI: 10.1136/jcp.43.7.584

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  13 in total

1.  Diagnosis of Pneumocystis carinii pneumonia: improved detection in sputum with use of monoclonal antibodies.

Authors:  J A Kovacs; V L Ng; H Masur; G Leoung; W K Hadley; G Evans; H C Lane; F P Ognibene; J Shelhamer; J E Parrillo
Journal:  N Engl J Med       Date:  1988-03-10       Impact factor: 91.245

Review 2.  Pneumocystosis. Current concepts and recent advances.

Authors:  K Salfelder; M Venezuela; J Schwarz
Journal:  Am J Dis Child       Date:  1967-12

3.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

4.  Propagation of Pneumocystis carinii in vitro.

Authors:  L L Pifer; W T Hughes; M J Murphy
Journal:  Pediatr Res       Date:  1977-04       Impact factor: 3.756

5.  Pulmonary complications of the acquired immunodeficiency syndrome. Report of a National Heart, Lung, and Blood Institute workshop.

Authors:  J F Murray; C P Felton; S M Garay; M S Gottlieb; P C Hopewell; D E Stover; A S Teirstein
Journal:  N Engl J Med       Date:  1984-06-21       Impact factor: 91.245

6.  Detection of circulating antigens of Pneumocystis carinii in human sera by a sandwich enzyme-immunoassay.

Authors:  K Tanabe; T Furuta
Journal:  Zentralbl Bakteriol Mikrobiol Hyg A       Date:  1987-05

7.  Cultivation of Pneumocystis carinii with WI-38 cells.

Authors:  M S Bartlett; P A Verbanac; J W Smith
Journal:  J Clin Microbiol       Date:  1979-12       Impact factor: 5.948

Review 8.  Pneumocystis carinii and Toxoplasma gondii infections in patients with AIDS.

Authors:  J Mills
Journal:  Rev Infect Dis       Date:  1986 Nov-Dec

9.  Growth and serial passage of Pneumocystis carinii in the A549 cell line.

Authors:  M T Cushion; P D Walzer
Journal:  Infect Immun       Date:  1984-05       Impact factor: 3.441

10.  The value of Pneumocystis carinii antibody and antigen detection for diagnosis of Pneumocystis carinii pneumonia after marrow transplantation.

Authors:  J D Meyers; L L Pifer; G E Sale; E D Thomas
Journal:  Am Rev Respir Dis       Date:  1979-12
View more
  2 in total

Review 1.  Immunological features of Pneumocystis carinii infection in humans.

Authors:  P D Walzer
Journal:  Clin Diagn Lab Immunol       Date:  1999-03

2.  Pneumocystis murina infection and cigarette smoke exposure interact to cause increased organism burden, development of airspace enlargement, and pulmonary inflammation in mice.

Authors:  Paul J Christensen; Angela M Preston; Tony Ling; Ming Du; W Bradley Fields; Jeffrey L Curtis; James M Beck
Journal:  Infect Immun       Date:  2008-05-19       Impact factor: 3.441

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.